The Catalyst – Deconstructing the High-Profile Exits
Recent announcements from major pharmaceutical players Novo Nordisk and Takeda regarding their withdrawal from cell therapy research and development have generated considerable industry discourse, fueling a narrative of a sector-wide retreat from this complex modality. However, a granular analysis of the strategic drivers behind these decisions reveals a more nuanced reality. These exits are not a referendum on the scientific or clinical potential of cell therapy itself. Instead, they represent proactive, internally-driven corporate recalibrations designed to optimize R&D portfolios, sharpen focus on core competencies, and maximize shareholder value in hyper-competitive markets. These moves are case studies in strategic discipline, not signs of a failing sector.
Case Study: Novo Nordisk’s Return to Core Identity
The decision by Danish pharmaceutical giant Novo Nordisk to shutter its entire cell therapy division in October 2025 was a direct and calculated consequence of a sweeping corporate overhaul initiated by its new CEO, Maziar Mike Doustdar.1 The new leadership established an aggressive mandate for change, centered on streamlining global operations to achieve approximately $1.25 billion to $1.3 billion in annual cost savings by the end of 2026. This far-reaching initiative involved a significant reduction of the company’s global workforce by 9,000 positions, representing about 11% of its total staff, and a rigorous assessment of all business areas to “simplify structures, reduce duplication and sharpen focus”.2
Within this stringent cost-cutting framework, the cell therapy unit was identified as a non-core asset. The division, which employed around 250 people, was pursuing ambitious, long-term, and capital-intensive R&D programs aimed at developing potentially curative therapies for Parkinson’s disease, chronic heart failure, and Type 1 diabetes. While scientifically promising, these programs represented a significant and uncertain future investment that stood in stark contrast to the CEO’s explicitly stated priority to “focus more on diabetes and obesity as this is our main core and always has been”.3 The decision to divest was a clear execution of the new strategic directive to “reallocate and look at our cost base and really put the money where the growth is”.
Crucially, this strategic pivot was not driven by a lack of capital but by a deliberate reallocation of it. Novo Nordisk’s financial health remains exceptionally robust, characterized by an impressive operating margin of 45.78% and a strong Altman Z-Score of 5.27, indicating a very low risk of financial distress.1 This financial strength underscores that the decision was a strategic choice made from a position of power, not a defensive measure born of necessity. The timing of the move further illuminates this reality. The announcement to close the cell therapy unit coincided with the company’s decisive $4.7 billion all-cash acquisition of Akero Therapeutics for its late-stage metabolic dysfunction-associated steatohepatitis (MASH) drug candidate.4 This major investment in a complementary metabolic asset serves as an unambiguous signal that capital was not being eliminated from the R&D budget but was being strategically redeployed to fortify its core, market-leading franchise.
This move represents a remarkably sharp reversal from the company’s prior public posture. As recently as its own corporate communications, Novo Nordisk was “aspiring to write the future of cell therapy,” backed by a “long-standing heritage of delivering innovative treatments”.5 The company had made substantial investments in the space, including a dedicated GMP manufacturing facility in Fremont, California, and had established global R&D centers to advance its cell therapy pipeline. The abruptness of this pivot, from aspiring leader to decisive exit, highlights that the decision was a top-down change in corporate strategy rather than a gradual disillusionment with the underlying science. The immense commercial success and intense competition in the GLP-1 agonist market for obesity and diabetes created a powerful opportunity cost. Maintaining leadership in this multi-billion-dollar arena requires an all-encompassing focus of capital and talent. From this perspective, funding a nascent, high-risk platform like cell therapy became a strategic diversion. The decision to sacrifice a “possible future” in cell therapy was a rational choice to secure a “dominant present” in metabolic disease.
Case Study: Takeda’s R&D Realignment
Takeda Pharmaceutical’s withdrawal from the cell therapy space, announced in early October 2025, was framed with a different, though equally strategic, rationale. Following disappointing clinical results of TAK-007 (that demonstrated NK memory lasting less than a median duration of 1 week and relapse control of less than 9 months across all dose levels)6, the Japanese pharma giant explicitly attributed its decision to a pragmatic assessment of the inherent challenges of the modality itself, citing “the struggles and high costs associated with bringing cell therapies to market, coupled with mounting safety and profitability concerns”7 . This reflects a clear-eyed evaluation of the uncertain returns and challenging development timelines that have characterized the first generation of cell therapies in the complex autologous space.
In place of cell therapy, Takeda announced a calculated shift in its R&D focus, redirecting near-term investments toward modalities it believes can deliver innovative therapies to patients “more efficiently and at greater scale”8. The company’s newly prioritized platforms are small molecules, biologics, and antibody-drug conjugates (ADCs)9 . This represents a strategic choice to optimize its R&D engine for platforms with more established development pathways, predictable manufacturing processes, and greater potential for scalability compared to the bespoke, logistically intensive nature of patient-specific cell therapies.
The financial and organizational impacts of this decision were significant. Takeda disclosed it would record an impairment loss of approximately 58 billion yen (nearly $395 million), primarily linked to intangible assets from its gamma delta T-cell platform, which it had invested in heavily through acquisitions like GammaDelta Therapeutics7. The strategic pivot also directly impacted about 137 employees.
However, similar to Novo Nordisk, Takeda is not simply writing off its investments. The company is actively seeking an “external partner” to acquire its cell therapy platforms and continue the advancement of its preclinical and clinic-ready programs7. This action indicates a belief that the underlying technology retains significant value, just not within Takeda’s newly defined strategic framework, which prioritizes efficiency and scale. Takeda’s exit highlights a growing bifurcation in R&D philosophies among major pharmaceutical companies. First-generation autologous cell therapies are the antithesis of a scalable, efficient modality; they are logistically complex, costly, and highly individualized. Takeda’s decision suggests that companies without a deep, pre-existing, and commercially successful foothold in cell therapy are now critically re-evaluating whether the high operational barriers are worth surmounting, especially when compared to the promise of other innovative platforms like ADCs. This creates a clear dividing line in the industry: on one side are companies that view cell therapy as a natural, albeit complex, extension of their biologics and oncology capabilities, and on the other are those that see it as a fundamentally different and operationally burdensome business model that falls outside their strategic appetite for risk and complexity.
The Counter-Narrative – Deepening Commitments and The Next Wave of Investment
While the strategic exits of Novo Nordisk and Takeda have captured headlines, they represent only one side of a bifurcating market. A formidable cohort of Big Pharma leaders is simultaneously executing a powerful counter-narrative, characterized by deepening commitments and massive, forward-looking investments. These companies are not merely maintaining their presence; they are aggressively investing tens of billions of dollars to build foundational infrastructure, acquire next-generation technologies, and scale their commercial successes. This wave of investment signals a profound confidence in the long-term, transformative potential of cell therapy and a strategic determination to lead its evolution.
The Established Leaders: Fortifying the Vanguard
The current commercial leaders in cell therapy, Bristol Myers Squibb and Gilead Sciences, are leveraging their market success to fund a strategic pivot toward the next technological frontier, ensuring their dominance extends into the future.
Bristol Myers Squibb (BMS): Pivoting to the Next Frontier
BMS has built a robust commercial foundation in the cell therapy market with two approved autologous CAR-T therapies, Abecma (idecabtagene vicleucel) for multiple myeloma and Breyanzi (lisocabtagene maraleucel) for lymphoma9 . These products are key drivers of the company’s growth portfolio and provide the strategic and financial latitude to invest in future innovation.
The company’s most significant recent move is the $1.5 billion all-cash acquisition of Orbital Therapeutics in October 2025, a clear and substantial bet on the next generation of cell therapy10 . Orbital is a pioneer of in vivo cell therapies, developing RNA-based medicines delivered via lipid nanoparticles (LNPs) that can reprogram a patient’s immune cells inside the body. This approach has the potential to eliminate the complex, costly, and time-consuming ex vivo manufacturing process that is a primary bottleneck for current autologous PBMC-derived CAR-T treatments. BMS’s strategic rationale was explicit: the acquisition “strengthens and diversifies” its cell therapy portfolio and provides a critical opportunity to advance a “potential best-in-class therapy” for autoimmune diseases- a vast and largely untapped market for cell therapies beyond oncology10. This move is not an incremental step but a decisive leap intended to position BMS at the forefront of the field’s technological evolution.
Further diversifying its next-generation portfolio, BMS has also previously invested heavily in “off-the-shelf” allogeneic platforms using induced pluripotent stem cells (iPSCs). In a strategic collaboration with Century Therapeutics, BMS is developing iPSC-derived natural killer (iNK) and T-cell (iT) therapies11. The partnership, initiated with a $150 million upfront payment and equity investment, could be worth over $3 billion in milestone payments. The initial focus was on developing therapies for challenging cancers like acute myeloid leukemia (AML) and multiple myeloma, complementing BMS’s then-existing cell therapy technologies and expanding its reach into scalable, patient-ready treatments. However, BMS recently axed this collaboration “without cause” under its new leadership, despite encouraging progress of the preclinical pipeline under the collaboration12. This termination was not an isolated move against cell therapy but a direct result of a sweeping internal restructuring at BMS. The decision is a component of a broader strategic initiative to achieve $1.5 billion in cost savings by the end of 2025, an effort that also included terminating partnerships for other modalities like antibody-drug conjugates and bispecific antibodies, alongside plans to reduce its workforce by over 2,200 employees13,14.
Gilead (Kite Pharma): Dominating the Present, Acquiring the Future
Gilead’s subsidiary, Kite Pharma, stands as the current market leader, having treated more patients with CAR-T therapy than any other company worldwide. Its flagship products, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), are commercially successful, generating combined sales of $2.0 billion in 2024, a 6% increase over the previous year15.
Following the same strategic logic as BMS, Kite is aggressively moving to secure its future leadership. In August 2025, Kite announced the acquisition of Interius BioTherapeutics for $350 million to integrate its complementary in vivo CAR T-cell platform16. The stated goal of this acquisition is to develop therapies that are “more accessible and scalable,” can “reduce treatment timelines,” and ultimately “broaden access to care”. These objectives directly address the primary limitations of first-generation PBMC-derived autologous cell therapies. Beyond technology acquisition, Gilead continues to pour investment into its manufacturing and supply chain, boasting an industry-leading median turnaround time of 14 days for autologous cell therapy in the U.S. and a 96% manufacturing success rate across its network of four commercial facilities17. With a pipeline advancing into new indications like autoimmune diseases and solid tumors using both iPSC and PBMC-derived cell therapies, Gilead is positioning itself to capture a significant share of a future cell therapy market projected to be worth over $40 billion.
Kite has also explored iPSC-derived allogeneic cell therapies as another avenue for next-generation treatments. The company entered a major strategic partnership with Shoreline Biosciences to develop “off-the-shelf” immunotherapies derived from iPSCs, focusing on CAR natural killer (NK) cells and macrophages18. The deal, potentially worth over $2.3 billion in milestone payments, aimed to combine Shoreline’s iPSC platform with Kite’s cell therapy expertise. However, demonstrating a dynamic and responsive R&D strategy, Kite terminated this collaboration in the first quarter of 2025, following termination of BeiGene-Shoreline collaboration19.
The Strategic Builders: Laying Foundational Infrastructure for Future Dominance
While the current leaders acquire next-generation technology, another group of pharmaceutical giants is making monumental, long-term capital investments to build the physical infrastructure required for future dominance in the cell and gene therapy space.
Novartis: Monumental Long-Term Commitment
As a pioneer in the field with the first approved CAR-T therapy, Kymriah (tisagenlecleucel), and the landmark gene therapy Zolgensma (onasemnogene abeparvovec), Novartis has a deep and enduring commitment to advanced therapies9. The company is now backing this commitment with an unprecedented level of capital expenditure. In April 2025, Novartis announced a planned $23 billion investment over five years in its U.S.-based R&D and manufacturing operations20.
This is not a speculative R&D budget but a massive, concrete investment in physical infrastructure. The plan explicitly supports the company’s most advanced technology platforms, with Novartis stating that it “already manufactures its most innovative, advanced therapies in the US… including cutting-edge technology platforms like gene and cell therapy” and that this investment will significantly expand that capacity20. The scope of the project is immense, involving the construction of seven entirely new facilities and the expansion of three existing ones, ensuring that Novartis will have end-to-end U.S. manufacturing capabilities for all its core technology platforms, including cell and gene therapy.
AstraZeneca (AZ): Building from the Ground Up
AstraZeneca is pursuing an equally ambitious infrastructure strategy. The company has pledged a staggering $50 billion investment in its U.S. manufacturing and R&D footprint by 2030, a long-term plan designed to support its corporate ambition of reaching $80 billion in annual revenue21. Critically, a significant portion of this capital is earmarked for cell therapy. The investment plan explicitly includes the construction of new, dedicated cell therapy manufacturing facilities in Rockville, Maryland, and Tarzana, California. This is an unequivocal, tangible signal of a long-term strategic commitment to building an internal, end-to-end cell therapy capability from the ground up. AZ’s strategic vision is to become a leader in “off-the-shelf” allogeneic cell therapies, which use healthy donor cells to overcome the scalability and accessibility challenges of personalized autologous treatments22 . The company is actively building its pipeline to feed this future manufacturing network through strategic partnerships with innovators like Quell Therapeutics (for regulatory T-cell therapies) and Cellectis (for gene-editing expertise).
Johnson & Johnson (J&J): Scaling Commercial Success
Johnson & Johnson’s cell therapy story is one of managing the immense success of its CAR-T therapy, Carvykti (ciltacabtagene autoleucel), which was co-developed with Legend Biotech. The therapy’s rapid uptake, especially after its FDA approval was expanded to earlier lines of multiple myeloma treatment in April 2024, has created significant supply constraints, a clear indicator of blockbuster demand23,24. In direct response to this high demand, J&J and Legend are making substantial investments to scale up their manufacturing capacity. In March 2025, the partners announced an additional $150 million investment to expand their new facility in Ghent, Belgium, with construction slated for completion in 2028 to primarily serve the European market. This follows a previous decision to double their investment to a total of $500 million in their flagship manufacturing site in Raritan, New Jersey. The overarching goal of these investments is to reach an annualized production capacity of 10,000 doses of Carvykti in 2025 and to expand the therapy’s administration into community oncology settings, demonstrating a clear focus on broadening patient access and maximizing market penetration.
Comparative Table: Big Pharma Cell Therapy Strategic Commitments (2024-2025)
The divergent paths being taken by major pharmaceutical companies are starkly illustrated when their recent strategic actions are compared directly. The following table summarizes the major investments and stated focus of the key players who are deepening their commitment to the cell therapy sector, providing a powerful, data-driven counterpoint to the “exodus” narrative.
| Company | Key Marketed Cell Therapy Products | Recent Major Cell Therapy Investments (2024-2025) |
| Bristol Myers Squibb | Abecma, Breyanzi | $1.5B acquisition of Orbital Therapeutics |
| Gilead (Kite) | Yescarta, Tecartus | $350M acquisition of Interius BioTherapeutics |
| Novartis | Kymriah | $23B 5-year investment in US ops (incl. CGT manufacturing) |
| AstraZeneca | GC012F (in Phase 1b/2) | $50B 5-year investment in US ops (incl. new cell therapy facilities) |
| Johnson & Johnson | Carvykti | $150M+ manufacturing expansion (Belgium) & $500M investment (NJ) |
The near-simultaneous, multi-billion-dollar investments by AstraZeneca and Novartis are not coincidental- they represent a strategic arms race to control what is seen as the next-generation solution to the modality’s primary limitations. The very “struggles” with cost, logistics, and complexity that Takeda cited for its exit are the exact problems that next-generation cell therapies (which aim to turn a complex medical procedure into a more scalable, off-the-shelf drug), are designed to solve. Their investments are therefore a strategic pre-emptive strike to capture and control this next-generation technology, ensuring their leadership persists. Furthermore, these massive infrastructure investments are about building a long-term, durable competitive advantage. Cell therapy manufacturing is not a simple addition to existing biologics facilities; it requires highly specialized expertise, technology, and quality control systems. Building this capacity takes years and billions of dollars, creating an enormous barrier to entry. By committing a combined $73 billion, Novartis and AstraZeneca are not just planning for one or two products; they are building foundational platforms capable of supporting an entire future portfolio of cell and gene therapies. This infrastructure becomes a strategic “moat,” enabling them to develop and launch future therapies faster and more cost-effectively than competitors and positioning them as the partners of choice for smaller biotechs with innovative science but no path to manufacturing.
Synthesis and Forward Outlook – A Market in Maturation
The seemingly contradictory actions within Big Pharma high-profile exits on one hand and massive investments on the other are not signs of a sector in crisis. Rather, they signal a market that is undergoing a natural and healthy maturation process. The initial, broad-based enthusiasm for cell therapy is giving way to a more sophisticated and strategically disciplined phase characterized by a clear bifurcation of corporate strategies and a decisive technological pivot toward solving the challenges of the first generation of these transformative medicines.
The Great Bifurcation: A Tale of Two Strategies
The current landscape is cleaving into two distinct strategic camps, each pursuing a rational and defensible path based on its unique corporate identity, risk tolerance, and market position.
The “Strategic Specialists” (e.g., Novo Nordisk, Takeda): This cohort is making a calculated decision to divest from a high-risk, operationally complex area to concentrate resources on its core strengths. For Novo Nordisk, this means doubling down on its dominant and highly profitable metabolic disease franchise. For Takeda, it means optimizing its R&D engine around more scalable and predictable modalities like biologics and ADCs. These moves are a hallmark of strategic discipline and a sharp focus on near-to-mid-term shareholder value. Their departure from the field is not a failure but a consolidation, making specialized talent and promising assets available for the more committed players.
The “Platform Leaders” (e.g., BMS, Gilead, Novartis, AZ, J&J): This cohort views cell therapy not as an experimental sideline but as a foundational pillar of twenty-first-century medicine. They are playing a long game, making the generational investments in next-generation technology and large-scale infrastructure (new manufacturing facilities) required to solve the modality’s current challenges. Their actions, backed by tens of billions of dollars in committed capital, signal an unwavering confidence in the long-term, multi-billion-dollar value proposition of cell and gene therapy. They are not just participating in the market; they are actively building the future of it.
The Technological Pivot: Solving the Problems of Generation One
The flow of investment capital provides the clearest signal of the industry’s future direction. The “smart money” is moving decisively toward platforms that directly address the bottlenecks of first-generation autologous therapies. The focus of the Platform Leaders is shifting from simply iterating on existing ex vivo autologous approaches to pioneering transformative new ones such as regenerative medicine and in vivo CAR therapies.
The primary targets for this investment are:
- Allogeneic (“Off-the-Shelf”) Therapies: As articulated in AstraZeneca’s corporate strategy, using healthy donor cells to create banks of patient-ready therapies is another key pathway to overcoming the logistical hurdles and patient-specific manufacturing timelines of autologous treatments22.
- In Vivo Therapies: As evidenced by the strategic acquisitions of Orbital Therapeutics by BMS10 and Interius BioTherapeutics by Gilead16, this is widely seen as a potent solution for scalability, accessibility, and cost-effectiveness. The ability to generate therapeutic cells directly within the patient’s body would revolutionize the treatment paradigm for auto-immune disorders and hematological malignancies.
This technological evolution is a direct and intelligent response to the market feedback and challenges that caused companies like Takeda to reconsider their position. The industry leaders are not ignoring the problems of the first generation; they are actively investing billions of dollars to solve them, a clear sign of a dynamic and maturing field. This transition can be understood as a move along the technology adoption S-curve. The cell therapy market is exiting the early, often hype-driven, “early adopter” phase and entering the more challenging, capital-intensive “growth” phase. This is a classic “shakeout” period where the true costs and complexities of scaling the technology are fully understood. Companies are now forced to make a definitive choice: commit the massive resources needed to lead and scale, or exit and focus on areas with a clearer path to return. This bifurcation is a sign of a healthy, consolidating market where the remaining players are highly capitalized and deeply committed, setting the stage for more sustainable long-term growth.
The strategic shifts at the Big Pharma level will inevitably create a ripple effect across the broader biotech ecosystem. The exits of Novo Nordisk and Takeda may create a temporary “chill” in venture funding for early-stage biotechs focused on ex vivo autologous platforms that do not offer a clear and compelling advantage over existing therapies. However, the massive infrastructure build-out by Novartis and AstraZeneca will create a future landscape where they become powerful partners or acquirers for biotechs that possess promising clinical assets but lack a viable path to commercial-scale manufacturing25. This bifurcation at the top of the industry will thus reshape the entire biotech funding and partnership landscape, rewarding next-generation innovation while significantly raising the bar for next-generation cell therapy approaches.